Silverfin false false 31/12/2024 01/01/2024 31/12/2024 Benjamin Birrell 03/12/2020 Katie Louise Birrell 28/03/2022 Tina Bolding 20/08/2024 03/12/2020 Dawn Dowds 28/03/2022 Beverley Jayne Harrow 11/09/2023 Zeeus Roy Thomas Stone 28/03/2022 11 April 2025 The principal activity of the company continued to be that of group management. 13060328 2024-12-31 13060328 bus:Director1 2024-12-31 13060328 bus:Director2 2024-12-31 13060328 bus:Director3 2024-12-31 13060328 bus:Director4 2024-12-31 13060328 bus:Director5 2024-12-31 13060328 bus:Director6 2024-12-31 13060328 2023-12-31 13060328 core:CurrentFinancialInstruments 2024-12-31 13060328 core:CurrentFinancialInstruments 2023-12-31 13060328 core:ShareCapital 2024-12-31 13060328 core:ShareCapital 2023-12-31 13060328 core:RetainedEarningsAccumulatedLosses 2024-12-31 13060328 core:RetainedEarningsAccumulatedLosses 2023-12-31 13060328 core:CostValuation 2023-12-31 13060328 core:DisposalsRepaymentsInvestments 2024-12-31 13060328 core:CostValuation 2024-12-31 13060328 2024-01-01 2024-12-31 13060328 bus:FilletedAccounts 2024-01-01 2024-12-31 13060328 bus:SmallEntities 2024-01-01 2024-12-31 13060328 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 13060328 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13060328 bus:Director1 2024-01-01 2024-12-31 13060328 bus:Director2 2024-01-01 2024-12-31 13060328 bus:Director3 2024-01-01 2024-12-31 13060328 bus:Director4 2024-01-01 2024-12-31 13060328 bus:Director5 2024-01-01 2024-12-31 13060328 bus:Director6 2024-01-01 2024-12-31 13060328 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure

Company No: 13060328 (England and Wales)

HAELAN PHARMACEUTICALS LIMITED

Unaudited Financial Statements
For the financial year ended 31 December 2024
Pages for filing with the registrar

HAELAN PHARMACEUTICALS LIMITED

Unaudited Financial Statements

For the financial year ended 31 December 2024

Contents

HAELAN PHARMACEUTICALS LIMITED

COMPANY INFORMATION

For the financial year ended 31 December 2024
HAELAN PHARMACEUTICALS LIMITED

COMPANY INFORMATION (continued)

For the financial year ended 31 December 2024
DIRECTORS Benjamin Birrell
Katie Louise Birrell
Tina Bolding (Resigned 20 August 2024)
Dawn Dowds
Beverley Jayne Harrow
Zeeus Roy Thomas Stone
SECRETARY Benjamin Birrell
REGISTERED OFFICE 4 The Traverse
Bury St. Edmunds
IP33 1BJ
United Kingdom
COMPANY NUMBER 13060328 (England and Wales)
CHARTERED ACCOUNTANTS Gascoynes
Gascoyne House
Moseleys Farm Business Centre
Fornham All Saints
Bury St Edmunds
Suffolk
IP28 6JY
HAELAN PHARMACEUTICALS LIMITED

BALANCE SHEET

As at 31 December 2024
HAELAN PHARMACEUTICALS LIMITED

BALANCE SHEET (continued)

As at 31 December 2024
Note 2024 2023
£ £
Fixed assets
Investments 3 480 1,520
480 1,520
Current assets
Stocks 4 214,212 0
Debtors 5 366,164 27,782
Cash at bank and in hand 15,700 9,004
596,076 36,786
Creditors: amounts falling due within one year 6 ( 32,157) ( 107,368)
Net current assets/(liabilities) 563,919 (70,582)
Total assets less current liabilities 564,399 (69,062)
Net assets/(liabilities) 564,399 ( 69,062)
Capital and reserves
Called-up share capital 1,600 1,600
Profit and loss account 562,799 ( 70,662 )
Total shareholders' funds/(deficit) 564,399 ( 69,062)

For the financial year ending 31 December 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

These financial statements have been prepared in accordance with the provisions of FRS 102 Section 1A – small entities. The financial statements of Haelan Pharmaceuticals Limited (registered number: 13060328) were approved and authorised for issue by the Board of Directors on 11 April 2025. They were signed on its behalf by:

Dawn Dowds
Director
HAELAN PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2024
HAELAN PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Haelan Pharmaceuticals Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 4 The Traverse, Bury St. Edmunds, IP33 1BJ, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including directors 6 5

3. Fixed asset investments

Other investments Total
£ £
Cost or valuation before impairment
At 01 January 2024 1,520 1,520
Disposals ( 1,040) ( 1,040)
At 31 December 2024 480 480
Carrying value at 31 December 2024 480 480
Carrying value at 31 December 2023 1,520 1,520

4. Stocks

2024 2023
£ £
Stocks 214,212 0

5. Debtors

2024 2023
£ £
Amounts owed by Group undertakings 307,508 24,132
Other debtors 58,656 3,650
366,164 27,782

6. Creditors: amounts falling due within one year

2024 2023
£ £
Trade creditors 10,781 792
Amounts owed to Group undertakings 0 109,584
Other taxation and social security 19,152 ( 3,008)
Other creditors 2,224 0
32,157 107,368

7. Related party transactions

Transactions with entities in which the entity itself has a participating interest

2024 2023
£ £
Balances owed by subsidiaries - Pura Health Limited 98,723 0
Balances owed to subsidiaries - The Original Alternative (Guernsey) Limited 0 109,583
Balances owed by subsidiaries - Greenleaf Analytics Limited 0 5,993
Balances owed by subsidiaries - The Original Alternative Limited 0 3,584
Balances owed by subsidiaries - CBD Clinics Limited 0 127
Balances owed by subsidiaries - CBD Brothers Gsy Ltd 0 125
Balances owed by subsidiaries - Celebrated Limited 0 867
Balances owed by subsidiaries - Greenleaf Processing Limited 208,786 13,436

Transactions with the entity's directors

2024 2023
£ £
Amount owed to Director - D Dowds 1,044 (10)
Amount owed to Director - K Birrell 0 35
Amount owed by Director - T Bolding 28,399 35
Amount owed by Director - Z Stone 786 0
Amount owed by Director - B Birrell 7,866 (995)